Search

Your search keyword '"Tushuizen, Maarten E."' showing total 334 results
Start Over Author "Tushuizen, Maarten E."
334 results on '"Tushuizen, Maarten E."'

51. Nonalcoholic fatty liver disease

Author

van Son, Koen C., (Onno) Holleboom, A. G., Tushuizen, Maarten E., Vascular Medicine, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Published
2023

52. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar

Author

Grobbee, Esmée J., primary, de Jong, Vivian D., additional, Schrieks, Ilse C., additional, Tushuizen, Maarten E., additional, Holleboom, Adriaan G., additional, Tardif, Jean-Claude, additional, Lincoff, A. Michael, additional, Schwartz, Gregory G., additional, Castro Cabezas, Manuel, additional, and Grobbee, Diederick E., additional

Published
2022
Full Text
View/download PDF

54. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Author

Liu, Cong, primary, Schönke, Milena, additional, Spoorenberg, Borah, additional, Lambooij, Joost M., additional, van der Zande, Hendrik J.P., additional, Zhou, Enchen, additional, Tushuizen, Maarten E., additional, Andréasson, Anne-Christine, additional, Park, Andrew, additional, Oldham, Stephanie, additional, Uhrbom, Martin, additional, Ahlstedt, Ingela, additional, Ikeda, Yasuhiro, additional, Wallenius, Kristina, additional, Peng, Xiao-Rong, additional, Guigas, Bruno, additional, Boon, Mariëtte R., additional, Wang, Yanan, additional, and Rensen, Patrick C.N., additional

Published
2022
Full Text
View/download PDF

55. Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands: the BELIVER study

Author

Furumaya, Alicia, primary, Haring, Martijn P D, additional, van Rosmalen, Belle V, additional, Klompenhouwer, Anne J, additional, Besselink, Marc G, additional, de Man, Robert A, additional, IJzermans, Jan N M, additional, Thomeer, Maarten G J, additional, Kramer, Matthijs, additional, Coolsen, Mariëlle M E, additional, Tushuizen, Maarten E, additional, Schaapherder, Alexander F, additional, de Haas, Robbert J, additional, Duiker, Evelien W, additional, Kazemier, Geert, additional, van Delden, Otto M, additional, Verheij, Joanne, additional, Takkenberg, R Bart, additional, Cuperus, Frans J C, additional, De Meijer, Vincent E, additional, and Erdmann, Joris I, additional

Published
2022
Full Text
View/download PDF

56. Left atrial dysfunction is an independent predictor of mortality in patients with cirrhosis treated by transjugular intrahepatic portosystemic shunt

Author

Meucci, Maria Chiara, primary, Hoogerduijn Strating, Merte M., additional, Butcher, Steele C., additional, van Rijswijk, Catharina S. P., additional, Van Hoek, Bart, additional, Delgado, Victoria, additional, Bax, Jeroen J., additional, Tushuizen, Maarten E., additional, and Marsan, Nina Ajmone, additional

Published
2022
Full Text
View/download PDF

57. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques

Author

Theel, Willy, primary, Boxma‐de Klerk, Bianca M., additional, Dirksmeier‐Harinck, Femme, additional, van Rossum, Elisabeth F. C., additional, Kanhai, Danny A., additional, Apers, Jan, additional, van Dalen, Bas M., additional, de Knegt, Robert J., additional, Holleboom, Anthony G., additional, Tushuizen, Maarten E., additional, Grobbee, Diederick E., additional, Wiebolt, Janneke, additional, and Castro Cabezas, Manuel, additional

Published
2022
Full Text
View/download PDF

59. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques

Author

Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Theel, Willy, Boxma-de Klerk, Bianca M., Dirksmeier-Harinck, Femme, van Rossum, Elisabeth F.C., Kanhai, Danny A., Apers, Jan, van Dalen, Bas M., de Knegt, Robert J., Holleboom, Anthony G., Tushuizen, Maarten E., Grobbee, Diederick E., Wiebolt, Janneke, Castro Cabezas, Manuel, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Theel, Willy, Boxma-de Klerk, Bianca M., Dirksmeier-Harinck, Femme, van Rossum, Elisabeth F.C., Kanhai, Danny A., Apers, Jan, van Dalen, Bas M., de Knegt, Robert J., Holleboom, Anthony G., Tushuizen, Maarten E., Grobbee, Diederick E., Wiebolt, Janneke, and Castro Cabezas, Manuel

Published
2022

60. Liver Injury and Acute Liver Failure after Bariatric Surgery: An Overview of Potential Injury Mechanisms

Author

Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Pharmaceutics, Moolenaar, Laura R., De Waard, Nadine E., Heger, Michal, De Haan, Lianne R., Slootmaekers, Caline P.J., Nijboer, Willemijn N., Tushuizen, Maarten E., Van Golen, Rowan F., Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Pharmaceutics, Moolenaar, Laura R., De Waard, Nadine E., Heger, Michal, De Haan, Lianne R., Slootmaekers, Caline P.J., Nijboer, Willemijn N., Tushuizen, Maarten E., and Van Golen, Rowan F.

Published
2022

61. Study Protocol PROMETHEUS:Prospective Multicenter Study to Evaluate the Correlation Between Safety Margin and Local Recurrence After Thermal Ablation Using Image Co-registration in Patients with Hepatocellular Carcinoma

Author

Oosterveer, Timo T.M., van Erp, Gonnie C.M., Hendriks, Pim, Broersen, Alexander, Overduin, Christiaan G., van Rijswijk, Carla S.P., van Erkel, Arian R., van der Meer, Rutger W., Tushuizen, Maarten E., Moelker, Adriaan, Meijerink, Martijn R., van Delden, Otto M., de Jong, Koert P., van der Leij, Christiaan, Smits, Maarten L.J., Urlings, Thijs A.J., Braak, Jeffrey P.B.M., Meershoek-Klein Kranenbarg, Elma, van Duijn-de Vreugd, Bianca, Zeijdner, Evelijn, Goeman, Jelle J., Fütterer, Jurgen J., Coenraad, Minneke J., Dijkstra, Jouke, Burgmans, Mark C., Oosterveer, Timo T.M., van Erp, Gonnie C.M., Hendriks, Pim, Broersen, Alexander, Overduin, Christiaan G., van Rijswijk, Carla S.P., van Erkel, Arian R., van der Meer, Rutger W., Tushuizen, Maarten E., Moelker, Adriaan, Meijerink, Martijn R., van Delden, Otto M., de Jong, Koert P., van der Leij, Christiaan, Smits, Maarten L.J., Urlings, Thijs A.J., Braak, Jeffrey P.B.M., Meershoek-Klein Kranenbarg, Elma, van Duijn-de Vreugd, Bianca, Zeijdner, Evelijn, Goeman, Jelle J., Fütterer, Jurgen J., Coenraad, Minneke J., Dijkstra, Jouke, and Burgmans, Mark C.

Abstract

Purpose: The primary objective is to determine the minimal ablation margin required to achieve a local recurrence rate of < 10% in patients with hepatocellular carcinoma undergoing thermal ablation. Secondary objectives are to analyze the correlation between ablation margins and local recurrence and to assess efficacy. Materials and Methods: This study is a prospective, multicenter, non-experimental, non-comparative, open-label study. Patients > 18 years with Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma (or B with a maximum of two lesions < 5 cm each) are eligible. Patients will undergo dual-phase contrast-enhanced computed tomography directly before and after ablation. Ablation margins will be quantitatively assessed using co-registration software, blinding assessors (i.e. two experienced radiologists) for outcome. Presence and location of recurrence are evaluated independently on follow-up scans by two other experienced radiologists, blinded for the quantitative margin analysis. A sample size of 189 tumors (~ 145 patients) is required to show with 80% power that the risk of local recurrence is confidently below 10%. A two-sided binomial z-test will be used to test the null hypothesis that the local recurrence rate is ≥ 10% for patients with a minimal ablation margin ≥ 2 mm. Logistic regression will be used to find the relationship between minimal ablation margins and local recurrence. Kaplan–Meier estimates are used to assess local and overall recurrence, disease-free and overall survival. Discussion: It is expected that this study will result in a clear understanding of the correlation between ablation margins and local recurrence. Using co-registration software in future patients undergoing ablation for hepatocellular carcinoma may improve intraprocedural evaluation of technical success. Trial registration The Netherlands Trial Register (NL9713), https://www.trialregister.nl/trial/9713.

Published
2022

62. Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands:the BELIVER study

Author

Furumaya, Alicia, Haring, Martijn P.D., Van Rosmalen, Belle V., Klompenhouwer, Anne J., Besselink, Marc G., De Man, Robert A., Ijzermans, Jan N.M., Thomeer, Maarten G.J., Kramer, Matthijs, Coolsen, Mariëlle M.E., Tushuizen, Maarten E., Schaapherder, Alexander F., De Haas, Robbert J., Duiker, Evelien W., Kazemier, Geert, Van Delden, Otto M., Verheij, Joanne, Takkenberg, R. Bart, Cuperus, Frans J.C., De Meijer, Vincent E., Erdmann, Joris I., Furumaya, Alicia, Haring, Martijn P.D., Van Rosmalen, Belle V., Klompenhouwer, Anne J., Besselink, Marc G., De Man, Robert A., Ijzermans, Jan N.M., Thomeer, Maarten G.J., Kramer, Matthijs, Coolsen, Mariëlle M.E., Tushuizen, Maarten E., Schaapherder, Alexander F., De Haas, Robbert J., Duiker, Evelien W., Kazemier, Geert, Van Delden, Otto M., Verheij, Joanne, Takkenberg, R. Bart, Cuperus, Frans J.C., De Meijer, Vincent E., and Erdmann, Joris I.

Abstract

Introduction Benign liver tumours and cysts (BLTCs) comprise a heterogeneous group of cystic and solid lesions, including hepatic haemangioma, focal nodular hyperplasia and hepatocellular adenoma. Some BLTCs, for example, (large) hepatocellular adenoma, are at risk of complications. Incidence of malignant degeneration or haemorrhage is low in most other BLTCs. Nevertheless, the diagnosis BLTC may carry a substantial burden and patients may be symptomatic, necessitating treatment. The indications for interventions remain matter of debate. The primary study aim is to investigate patient-reported outcomes (PROs) of patients with BLTCs, with special regards to the influence of invasive treatment as compared with the natural course of the disease. Methods and analysis A nationwide observational cohort study of patients with BLTC will be performed between October 2021 and October 2026, the minimal follow-up will be 2 years. During surveillance, a questionnaire regarding symptoms and their impact will be sent to participants on a biannual basis and more often in case of invasive intervention. The questionnaire was previously developed based on PROs considered relevant to patients with BLTCs and their caregivers. Most questionnaires will be administered by computerised adaptive testing through the Patient-Reported Outcomes Measurement Information System. Data, such as treatment outcomes, will be extracted from electronic patient files. Multivariable analysis will be performed to identify patient and tumour characteristics associated with significant improvement in PROs or a complicated postoperative course. Ethics and dissemination The study was assessed by the Medical Ethics Committee of the University Medical Center Groningen and the Amsterdam UMC. Local consultants will provide information and informed consent will be asked of all patients. Results will be published in a peer-reviewed journal. Study registration NL8231 - 10 December 2019; Netherlands Trial Register.

Published
2022

67. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.

Author

Cong Liu, Schönke, Milena, Spoorenberg, Borah, Lambooij, Joost M., van der Zande, Hendrik J. P., Enchen Zhou, Tushuizen, Maarten E., Andreasson, Anne-Christine, Park, Andrew, Oldham, Stephanie, Uhrbom, Martin, Ahlstedt, Ingela, Yasuhiro Ikeda, Wallenius, Kristina, Xiao-Rong Peng, Guigas, Bruno, Boon, Mariëtte R., Yanan Wang, and Rensen, Patrick C. N.

Published
2023
Full Text
View/download PDF

70. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease

Author

Van Dijk, Anne-Marieke, primary, Vali, Yasaman, additional, Mak, Anne Linde, additional, Lee, Jenny, additional, Tushuizen, Maarten E., additional, Zafarmand, Mohammad Hadi, additional, Anstee, Quentin M., additional, Brosnan, M. Julia, additional, Nieuwdorp, Max, additional, Bossuyt, Patrick M., additional, and Holleboom, Adriaan G., additional

Published
2021
Full Text
View/download PDF

73. Niet-alcoholische leververvetting Een lijvige epidemie

Author

Tushuizen, Maarten E., Holleboom, A. G., Koot, P., Blokzijl, Hans, van Mil, Saskia W. C., Koek, Ger H., Vascular Medicine, ACS - Diabetes & metabolism, AGEM - Endocrinology, metabolism and nutrition, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, and Tytgat Institute for Liver and Intestinal Research

Published
2020

83. Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis

Author

van Dam, Lisette F., additional, Klok, Frederikus A., additional, Tushuizen, Maarten E., additional, Ageno, Walter, additional, Darwish Murad, Sarwa, additional, van Haren, Guido R., additional, Huisman, Menno V., additional, Lauw, Mandy N., additional, Iglesias del Sol, Antonio, additional, Wasser, Martin N.J.M., additional, Willink, Ysbrand, additional, and Kroft, Lucia J.M., additional

Published
2020
Full Text
View/download PDF

90. Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course.

Author

van Rosmalen, Belle V., Furumaya, Alicia, Klompenhouwer, Anne J., Tushuizen, Maarten E., Braat, Andries E., Reinten, Roy J., Ligthart, Marjolein A. P., Haring, Martijn P. D., de Meijer, Vincent E., van Voorthuizen, Theo, Takkenberg, R. Bart, Dejong, Cornelis H. C., de Man, Robert A., IJzermans, Jan N. M., Doukas, Michail, van Gulik, Thomas M., and Verheij, Joanne

Subjects
CLINICAL pathology, ADENOMA, CURRICULUM, HISTOPATHOLOGY, DIAGNOSIS, HEPATOCELLULAR carcinoma
Abstract

Background & Aims: Hepatocellular adenomas (HCA) rarely occur in males, and if so, are frequently associated with malignant transformation. Guidelines are based on small numbers of patients and advise resection of HCA in male patients, irrespective of size or subtype. This nationwide retrospective cohort study is the largest series of HCA in men correlating (immuno)histopathological and molecular findings with the clinical course. Methods: Dutch male patients with available histological slides with a (differential) diagnosis of HCA between 2000 and 2017 were identified through the Dutch Pathology Registry (PALGA). Histopathology and immunohistochemistry according to international guidelines were revised by two expert hepatopathologists. Next generation sequencing (NGS) was performed to confirm hepatocellular carcinoma (HCC) and/or subtype HCA. Final pathological diagnosis was correlated with recurrence, metastasis and death. Results: A total of 66 patients from 26 centres fulfilling the inclusion criteria with a mean (±SD) age of 45.0 ± 21.6 years were included. The diagnosis was changed after expert revision and NGS in 33 of the 66 patients (50%). After a median follow‐up of 9.6 years, tumour‐related mortality of patients with accessible clinical data was 1/18 (5.6%) in HCA, 5/14 (35.7%) in uncertain HCA/HCC and 4/9 (44.4%) in the HCC groups (P =.031). Four B‐catenin mutated HCA were identified using NGS, which were not yet identified by immunohistochemistry and expert revision. Conclusions: Expert revision with relevant immunohistochemistry may help the challenging but prognostically relevant distinction between HCA and well‐differentiated HCC in male patients. NGS may be more important to subtype HCA than indicated in present guidelines. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

91. Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.

Author

Schaapman, Jelte J., Tushuizen, Maarten E., Coenraad, Minneke J., and Lamb, Hildo J.

Subjects
FATTY liver, NON-alcoholic fatty liver disease, MAGNETIC resonance imaging, LIVER diseases, DIAGNOSIS, LIVER biopsy
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease in the world, affecting more than 25% of the adult population. NAFLD covers a spectrum including simple steatosis, in which lipid accumulation in hepatocytes is the predominant histological characteristic, and nonalcoholic steatohepatitis (NASH), which is characterized by additional hepatic inflammation with or without fibrosis. Liver biopsy is currently the reference standard to discriminate between hepatic steatosis and steatohepatitis. Since liver biopsy has several disadvantages, noninvasive diagnostic methods with high sensitivity and specificity are desirable for the analysis of NAFLD. Improvements in magnetic resonance imaging (MRI) technology are continuously being implemented in clinical practice, specifically multiparametric MRI methods such as proton density fat‐fraction (PDFF), T2*, and T1 mapping, along with MR elastography. Multiparametric imaging of the liver has a promising role in the clinical management of NAFLD with quantification of fat content, iron load, and fibrosis, which are features in NAFLD. In the present article, we review the utility and limitations of multiparametric quantitative imaging of the liver for diagnosis and management of patients with NAFLD. Level of Evidence: 5. Technical Efficacy Stage: 3. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

93. Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease.

Author

Ruissen, Merel M., Mak, Anne Linde, Beuers, Ulrich, Tushuizen, Maarten E., and Holleboom, Adriaan G.

Subjects
LIVER diseases, HEART metabolism disorders, DIAGNOSTIC services, FATTY liver, PATHOLOGY
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a growing health p roblem with a global prevalence of over 25% and prevalence rates of over 60% in high-risk populations. It is co nsidered the hepatic component of the metabolic syndrome and is associated with an increased risk of the develo pment of various liver-associated and cardiometabolic complications. Given the complexity of NAFLD and associated com orbidities and complications, treatment requires interventions from a variety of different healthcare specialties. However, many clinicians are currently insufficiently aware of the potential harm and severity of NAFLD and associate d comorbidities, complications and the steps that should be taken when NAFLD is suspected. Recognizing which pati ents suffer from non-progressive simple steatosis, metabolically active NASH with high risk of developing cardiova scular disease and which patients have a high risk of developing cirrhosis and hepatocellular carcinoma is important. Unfortunately, this can be difficult and guidelines towards the optimal diagnostic and therapeutic approach are amb ivalent. Here we review the pathogenesis, diagnostics and treatment of NAFLD and discuss how multidiscipl inary care path development could move forward. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

97. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands

Author

van den Brand, Floris F., primary, van Nieuwkerk, Carin M. J., additional, Verwer, Bart J., additional, de Boer, Ynto S., additional, de Boer, Nanne K. H., additional, Mulder, Chris J. J., additional, Bloemena, Elisabeth, additional, Bakker, Christine M., additional, Vrolijk, Jan M., additional, Drenth, Joost P. H., additional, Tan, Adriaan C. I. T. L., additional, ter Borg, Frank, additional, ter Borg, Martijn J., additional, van den Hazel, Sven J., additional, Inderson, Akin, additional, Tushuizen, Maarten E., additional, and Bouma, Gerd, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results